Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Aim Immunotech Inc (AIM)

Aim Immunotech Inc (AIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 18,259
  • Shares Outstanding, K 48,049
  • Annual Sales, $ 140 K
  • Annual Income, $ -19,130 K
  • 60-Month Beta -0.40
  • Price/Sales 141.44
  • Price/Cash Flow N/A
  • Price/Book 0.45
Trade AIM with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.43
  • Most Recent Earnings -0.13 on 11/15/22
  • Next Earnings Date N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3701 +7.19%
on 12/08/22
0.5212 -23.89%
on 11/15/22
-0.1148 (-22.44%)
since 11/08/22
3-Month
0.3701 +7.19%
on 12/08/22
0.6800 -41.66%
on 09/15/22
-0.2345 (-37.15%)
since 09/08/22
52-Week
0.3701 +7.19%
on 12/08/22
1.4200 -72.06%
on 12/09/21
-1.0333 (-72.26%)
since 12/08/21

Most Recent Stories

More News
AIM ImmunoTech Announces Corporate Governance Enhancements

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the following corporate governance enhancements:

AIM : 0.3967 (+4.39%)
AIM ImmunoTech Shareholders Elect All Three Company Director Nominees at 2022 Annual Meeting

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that shareholders have re-elected all three of the Company’s directors, Stewart L. Appelrouth, Thomas K. Equels...

AIM : 0.3967 (+4.39%)
Delaware Court Rules in Favor of AIM ImmunoTech and Declines to Declare Activist Group’s Nominations Valid

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”) today announced that the Delaware Court of Chancery has denied Jonathan Jorgl’s motion for a mandatory preliminary injunction...

AIM : 0.3967 (+4.39%)
AIM ImmunoTech Board Issues Letter to Shareholders

The Board of Directors (“Board”) of AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”) today issued a letter to shareholders to correct the record around recent false and misleading...

AIM : 0.3967 (+4.39%)
AIM ImmunoTech Board Files Definitive Proxy Statement and Sends Letter to Shareholders

The Board of Directors (“Board”) of AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), today announced that the Company has filed its Definitive Proxy Statement in connection...

AIM : 0.3967 (+4.39%)
AIM ImmunoTech Provides Update on Jorgl Activist Group Litigation

AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders,...

AIM : 0.3967 (+4.39%)
AIM ImmunoTech Reports Positive Pilot Study Data from Expanded Access Program Evaluating Ampligen® for the Treatment of Long COVID

Growing body of data supports Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for a Phase 2 study of...

AIM : 0.3967 (+4.39%)
AIM ImmunoTech reports additional patient data from Single-Center Named Patient Program evaluating Ampligen as maintenance therapy for advanced pancreatic cancer indicating additional progression-free and overall survival over previously published data

Ampligen® (rintatolimod) has demonstrated promising activity as a potential maintenance therapy after systemic chemotherapy in patients with metastatic and...

AIM : 0.3967 (+4.39%)
AIM ImmunoTech Announces that Recently Received Director Nominations from Jorgl Activist Group are Invalid

Files Complaint in Federal Court to Compel Activist Group to Reveal True Intentions – Including a Potential Hostile Takeover of the Company – and Prevent...

AIM : 0.3967 (+4.39%)
AIM ImmunoTech to Present at the Virtual Investor Innovations in Oncology Spotlight Series

Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leader Professor C.H.J. van Eijck, MD...

AIM : 0.3967 (+4.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases. The company's flagship products include Ampligen(R), Rintamod(R) and Alferon N Injection(R) which are in clinical stage. AIM...

See More

Key Turning Points

3rd Resistance Point 0.4078
2nd Resistance Point 0.4023
1st Resistance Point 0.3911
Last Price 0.3967
1st Support Level 0.3744
2nd Support Level 0.3689
3rd Support Level 0.3577

See More

52-Week High 1.4200
Fibonacci 61.8% 1.0189
Fibonacci 50% 0.8950
Fibonacci 38.2% 0.7712
Last Price 0.3967
52-Week Low 0.3701

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar